Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
Deciphering the dynamic changes in antibodies against SARS-CoV-2 is essential for
understanding the immune response in COVID-19 patients. Here we analyze the laboratory …
understanding the immune response in COVID-19 patients. Here we analyze the laboratory …
Humoral responses and serological assays in SARS-CoV-2 infections
Y Galipeau, M Greig, G Liu, M Driedger… - Frontiers in …, 2020 - frontiersin.org
In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
NYL Pang, ASR Pang, VT Chow, DY Wang - Military Medical Research, 2021 - Springer
SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
A comprehensive review of the protein subunit vaccines against COVID-19
Two years after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in
December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 …
December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 …
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …
Two years into the COVID-19 pandemic: lessons learned
SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
Hyperinflammatory immune response and COVID-19: a double edged sword
LY Tan, TV Komarasamy… - Frontiers in …, 2021 - frontiersin.org
The coronavirus disease-19 (COVID-19) elicited by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has caused devastating health, economic and social impact …
coronavirus 2 (SARS-CoV-2) has caused devastating health, economic and social impact …
[HTML][HTML] Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
J Lopez, M Mommert, W Mouton, A Pizzorno… - Journal of Experimental …, 2021 - rupress.org
IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3 …
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3 …
Pathophysiology of COVID-19: mechanisms underlying disease severity and progression
MK Bohn, A Hall, L Sepiashvili, B Jung… - …, 2020 - journals.physiology.org
The global epidemiology of coronavirus disease 2019 (COVID-19) suggests a wide
spectrum of clinical severity, ranging from asymptomatic to fatal. Although the clinical and …
spectrum of clinical severity, ranging from asymptomatic to fatal. Although the clinical and …
COVID-19: challenges of viral variants
JL Jacobs, G Haidar, JW Mellors - Annual Review of Medicine, 2023 - annualreviews.org
The COVID-19 pandemic has been accompanied by SARS-CoV-2 evolution and
emergence of viral variants that have far exceeded initial expectations. Five major variants of …
emergence of viral variants that have far exceeded initial expectations. Five major variants of …